stockportfolio.pro
Assembly Biosciences, Inc. (ASMB)
Healthcare · Biotechnology · NasdaqGS
Assembly Biosciences, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $9.02M | $14.80M | $15.96M | $79.11M | $6.25M | $0 | $7.16M | $28.52M | $72.30M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-44.26M | $-42.81M | $-90.75M | $-97.63M | $-62.15M | $-129.85M | $-93.09M | $-61.23M | $-40.18M | $-6.12M |
| Net margin | — | -474.7% | -613.0% | -611.6% | -78.6% | -2076.4% | — | -854.8% | -140.9% | -8.5% |
Source: Assembly Biosciences, Inc. SEC filings (10-K). 19 years of history available in the interactive view.
Explore 19 years of Assembly Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ASMB in your portfolio →
Assembly Biosciences, Inc. financial history by metric
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Assembly Biosciences, Inc. — frequently asked questions
What is Assembly Biosciences, Inc.'s revenue?
Assembly Biosciences, Inc. (ASMB) reported revenue of $72.30M for fiscal year 2025, up 153.5% from the prior year, according to its SEC filings.
Is Assembly Biosciences, Inc. profitable?
No — ASMB reported a net loss of $-6.12M in fiscal 2025.
What is ASMB's P/E ratio?
Assembly Biosciences, Inc. trades at a price-to-earnings ratio of about 275.2 based on the latest data in our nightly-refreshed cache.
How fast is Assembly Biosciences, Inc. growing?
ASMB's revenue grew at roughly -1.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Assembly Biosciences, Inc. have?
As of fiscal year 2025, ASMB carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Assembly Biosciences, Inc.'s market cap?
Assembly Biosciences, Inc. (ASMB) has a market capitalization of about $436.28M, based on the latest data in our nightly-refreshed cache.
When does Assembly Biosciences, Inc.'s fiscal year end?
ASMB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Assembly Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.